Skip to main content
Premium Trial:

Request an Annual Quote

Deadline for Receiving Bioinformatics IDL Comments May Extend

Premium

CLEVELAND, Ohio--Leaders of an effort to develop industry-wide bioinformatics software standards will decide this week whether to continue seeking comments from interested parties, or to stand pat with the 13 sets of comments they have already received. Bioinform atics companies and researchers faced a November 10 deadline for offering comments on developing common standards for an Interface Definition Language that will allow researchers to easily share software objects and data (see BioInform, October 13). But Eric Neumann of bioinformatics software company NetGenics here, told BioInform that the comment period may be extended to mid-January so that more companies and scientists can participate.

Whatever the final decision on the extension, Neumann and other bioinformatics professionals will review the comments received so far at a meeting of the Object Management Group in East Brunswick, NJ, December 2. The group is a nonprofit industry consortium that endorses standards and promotes sharable object software. Its members will eventually vote on whatever IDL standard is proposed.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.